LINCOLN

Lincoln Pharmaceuticals Share PriceLincoln Pharmaceuticals

₹677.85
5.2 (0.77%)
As on 01 December, 2023 | 22:28 BSE: 531633 NSE: LINCOLNISIN: INE405C01035

Lincoln Pharmaceuticals Performance

Day Range

  • Low 671.00
  • High 689.00
₹ 677.85

52 Week Range

  • Low 300.00
  • High 692.00
₹ 677.85
  • Open Price685.00
  • Previous Close672.65
  • Volume100662

Start SIP in Lincoln Pharmaceuticals

Start SIP

Lincoln Pharmaceuticals Share Price

  • Over 1 Month 37.01%
  • Over 3 Month 32.92%
  • Over 6 Month 77.77%
  • Over 1 Year 98.87%

Lincoln Pharmaceuticals Key Statistics

P/E Ratio 16.8
PEG Ratio
Market Cap Cr 1,358
Price to Book Ratio 2.7
EPS 36.2
Dividend 0.2
Relative Strength Index 73.95
Money Flow Index 83.77
MACD Signal 33.43
Average True Range 26.05

Lincoln Pharmaceuticals Investment Rating

  • Master Rating:
  • Lincoln Pharmaceuticals has an operating revenue of Rs. 537.83 Cr. on a trailing 12-month basis. An annual revenue growth of 11% is good, Pre-tax margin of 20% is great, ROE of 14% is good. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is comfortably placed above its key moving averages, around 23% and 53% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 23% from the pivot point (which is extended from the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 82 which is a GOOD score indicating consistency in earnings, a RS Rating of 85 which is GOOD indicating the outperformance as compared to other stocks, Buyer Demand at A+ which is evident from recent demand for the stock, Group Rank of 75 indicates it belongs to a poor industry group of Medical-Diversified and a Master Score of B is close to being the best. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has great fundamentals and technical strength to stay in momentum.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Lincoln Pharmaceuticals Financials
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 156136112134141123103
Operating Expenses Qtr Cr 1251159610711210785
Operating Profit Qtr Cr 31211727291717
Depreciation Qtr Cr 3322222
Interest Qtr Cr 0010001
Tax Qtr Cr 9649866
Net Profit Qtr Cr 28191322241511
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 533482
Operating Expenses Annual Cr 421377
Operating Profit Annual in Cr 8995
Depreciation Cr 98
Interest Annual Cr 21
Tax Annual Cr 2827
Net Profit Annual Cr 7369
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 76
Cash from Investing Activity Annual Cr -78
Cash from Financing Annual Activity Cr -3
Net Cash Flow Annual Cr -4
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 502433
Fixed Assets Annual Cr 157148
Total Non Current Assets Annual Cr 220182
Total Current Assets Annual Cr 367353
Total Assets Annual Cr 587534
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 251216
ROE Annual % 1516
ROCE Annual % 2022
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2222
IndicatorSep 2023Jun 2023Mar 2023Dec 2022Sep 2022Jun 2022Mar 2022
Oper Rev Qtr Cr 156136112134141123103
Operating Expenses Qtr Cr 1251159610711210785
Operating Profit Qtr Cr 31211727291717
Depreciation Qtr Cr 3322222
Interest Qtr Cr 0010001
Tax Qtr Cr 9649866
Net Profit Qtr Cr 28191322241511
IndicatorMar 2023Mar 2022
Total Revenue Annual Cr 533482
Operating Expenses Annual Cr 421377
Operating Profit Annual in Cr 8995
Depreciation Cr 98
Interest Annual Cr 21
Tax Annual Cr 2827
Net Profit Annual Cr 7369
IndicatorMar 2023Mar 2022
Cash from Operating Activity Annual Cr 3976
Cash from Investing Activity Annual Cr -37-78
Cash from Financing Annual Activity Cr -5-3
Net Cash Flow Annual Cr -2-5
IndicatorMar 2023Mar 2022
Total ShareHolders Funds Annual Cr 502433
Fixed Assets Annual Cr 157148
Total Non Current Assets Annual Cr 220182
Total Current Assets Annual Cr 367353
Total Assets Annual Cr 587534
IndicatorMar 2023Mar 2022
Book Value Per Share Annual Rs 251216
ROE Annual % 1516
ROCE Annual % 2022
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 2222

Lincoln Pharmaceuticals Technicals

EMA & SMA

Current Price
₹677.85
5.2 (0.77%)
pointer
  • Bullish Moving Average
  • ___
  • 16
  • Bearish Moving Average
  • ___
  • 0
  • 20 Day
  • ₹615.75
  • 50 Day
  • ₹563.81
  • 100 Day
  • ₹517.02
  • 200 Day
  • ₹461.96
  • 20 Day
  • ₹612.07
  • 50 Day
  • ₹547.07
  • 100 Day
  • ₹504.46
  • 200 Day
  • ₹440.04

Lincoln Pharmaceuticals Resistance and Support

PIVOT
₹679.29
Resistance
First Resistance 687.57
Second Resistance 697.28
Third Resistance 705.57
RSI 73.95
MFI 83.77
MACD Single Line 33.43
MACD 37.82
Support
First Resistance 669.57
Second Resistance 661.28
Third Resistance 651.57

Lincoln Pharmaceuticals Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 106,560 5,179,882 48.61
Week 146,606 6,098,799 41.6
1 Month 355,293 8,733,090 24.58
6 Month 166,910 6,859,989 41.1

Lincoln Pharmaceuticals Result Highlights

Lincoln Pharmaceuticals Synopsis

NSE-Medical-Diversified

Lincoln Pharmace is involved in the business activities of Manufacture of pharmaceuticals, medicinal chemical and botanical products. Company’s Total Operating Revenue is Rs. 510.31 Cr. and Equity Capital is Rs. 20.03 Cr. for the Year ended 31/03/2023. Lincoln Pharmaceuticals Ltd. is a Public Limited Listed company incorporated on 20/01/1995 and has its registered office in the State of Gujarat, India. Company’s Corporate Identification Number(CIN) is L24230GJ1995PLC024288 and registration number is 024288.
Market Cap 1,358
Sales 538
Shares in Float 0.98
No of funds 12
Yield 0.23
Book Value 2.71
U/D Vol ratio 4
LTDebt / Equity
Alpha 0.25
Beta 0.9

Lincoln Pharmaceuticals

Owner NameSep-23Jun-23Mar-23Dec-22
Promoters 50.53%48.67%47%46.34%
Mutual Funds
Foreign Portfolio Investors 2.59%1.74%1.27%1.44%
Individual Investors 37.47%37.32%37.04%36.61%
Others 9.41%12.27%14.69%15.61%

Lincoln Pharmaceuticals Management

Name Designation
Mr. Kishor M Shah Chairman
Mr. Mahendra G Patel Managing Director
Mr. Hashmukh I Patel Whole Time Director
Mr. Munjal M Patel Whole Time Director
Mr. Ashish R Patel Whole Time Director
Mr. Rajnikant G Patel Director
Mr. Ishwarlal A Patel Independent Director
Mr. Pirabhai R Suthar Independent Director
Mr. Meha M Patel Independent Director
Mr. Saurin J Parikh Independent Director

Lincoln Pharmaceuticals Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Lincoln Pharmaceuticals Corporate Action

Date Purpose Remarks
2023-11-02 Quarterly Results
2023-08-10 Quarterly Results
2023-05-25 Audited Results & Dividend
2023-02-09 Quarterly Results
2022-11-10 Quarterly Results

Lincoln Pharmaceuticals MF Shareholding

Name Amount(cr)
Motilal Oswal S&P BSE Healthcare ETF 8

Lincoln Pharmaceuticals FAQs

What is Share Price of Lincoln Pharmaceuticals ?

Lincoln Pharmaceuticals share price is ₹677 As on 01 December, 2023 | 22:14

What is the Market Cap of Lincoln Pharmaceuticals ?

The Market Cap of Lincoln Pharmaceuticals is ₹1357.7 Cr As on 01 December, 2023 | 22:14

What is the P/E ratio of Lincoln Pharmaceuticals ?

The P/E ratio of Lincoln Pharmaceuticals is 16.8 As on 01 December, 2023 | 22:14

What is the PB ratio of Lincoln Pharmaceuticals ?

The PB ratio of Lincoln Pharmaceuticals is 2.7 As on 01 December, 2023 | 22:14

Q2FY23